ADP REAGENT Adenosine-5'-Diphosphate
ADP Reagent Reveals Key Aggregation Platelet Responses
ADP Reagent (Adenosine-5'-Diphosphate) is for routine use in eliciting a concentration dependent activation or aggregation response in a Platelet Rich Plasma sample.
-
Induces Platelet Shape Change
-
Causes Primary Platelet Aggregation
-
Generates Thromboxane A2
-
Enhances Secondary Aggregation Induced by Granule Release
-
Indicates Occurrence of Disaggregation Response
-
Shows Blockade Effects on P2Y1, P2Y12, and P2X1 Receptors
-
Displays Effects of LVAD on Platelet Function
Catalog No.: 101312
Net Contents: 3 x 0.5 mL
When introduced into platelet-rich plasma, the ADP (Adenosine-5'-Diphosphate) reagent emerges as a powerful catalyst, orchestrating a multifaceted sequence of events within the realm of platelet dynamics. The initial phase of this orchestrated response is marked by a striking transformation in the shape of platelets, coupled with the formation of aggregates.
This primary aggregation, induced by the exogenous administration of ADP, is aptly termed "primary aggregation." Notably, this phase is characterized by its reversible nature, underlining the dynamic adaptability of platelets in the presence of ADP. However, the narrative doesn't end here; normal platelets, in a subsequent maneuver, escalate the complexity of their response by releasing endogenous ADP from their granules.
This release of endogenous ADP serves as a trigger for a secondary wave of aggregation, distinctive in its irreversibility. This secondary aggregation unveils a deeper layer of platelet behavior, shedding light on the nuanced interplay between exogenous and endogenous ADP. The reversible primary aggregation and the irreversible secondary aggregation collectively contribute to a comprehensive understanding of the intricate and sequential facets of platelet behavior in response to ADP stimulation.
This intricate dance of platelets, choreographed by the influence of ADP, not only unravels the immediate responses in platelet shape and aggregation but also underscores the nuanced regulatory mechanisms at play within the dynamic milieu of platelet-rich plasma. As we delve into the intricacies of these responses, we gain a richer perspective on the complexity of platelet biology and the subtle orchestration of events initiated by the introduction of ADP.
Please explore the literature provided, encompassing the ADP Reagent Product Data Sheet, Routine Agonist Expected Results Chart, and the ADP Instruction for Use (IFU), along with the ADP Safety Data Sheet (SDS) — both available in six languages. Additionally, for our European and United Kingdom customers and distributors, review the ADP EU Declaration of Conformity and the ADP UK Declaration of Conformity, to ensure compliance and understanding tailored specifically for these regions. This information is crucial for a comprehensive grasp of the product details and specifications.